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In recent years there have been major advances in our knowledge of the regulation of iron metabolism that have had implications
for understanding the pathophysiology of some human disorders like beta-thalassemia and other iron overload diseases. However,
little is known about the relationship among ineﬀective erythropoiesis, the role of iron-regulatory genes, and tissue iron
distribution in beta-thalassemia. The principal aim of this paper is an update about the role of Ferroportin during human
normal and pathological erythroid diﬀerentiation. Particular attention will be given to beta-thalassemia and other diseases with
iron overload. Recent discoveries indicate that there is a potential for therapeutic intervention in beta-thalassemia by means of
manipulating iron metabolism.
1. Identiﬁcation, Tissue Distribution,
andS tructuralF eatur eso fF e rr o po rtin
Ferroportin (FPN1, also known as Ireg 1 or MTP1), the
product of SLC40A1 gene, was independently identiﬁed by
three groups, using diﬀerent approaches [1–3]. FPN1 has
been reported to be expressed and to play a critical role
in several diﬀerent tissues involved in mammalian iron
homeostasis, including duodenal enterocytes (iron uptake
and export into circulation), hepatocytes (storage), syncy-
tiotrophoblasts (transfer to embryo) and reticuloendothelial
macrophages (iron recycling from senescent red blood cells)
[4]. FPN1 appears to act as an iron exporter [2, 3]a n dt o
bespeciﬁcallyregulatedaccordingtobodyironrequirements
in these tissues [2, 4–9]. The FPN1 gene is highly conserved
during evolution and encodes for a protein 571 aa in
length with a predicted mass of 62KDa [1, 3]. Sequence
data showed that FPN1 is a multipass integral membrane
protein iron exporter and has at least nine transmembrane
alphahelices [1–3]. The locations of N- and C-termini have
been largely debated in previous studies indicating for one
or both termini an extracellular [10–12] or an intracellular
location [13–15]( Figure 1). Diﬀerent results have also been
obtained for the membrane topology of FPN1 and the
number of its TM domains [2, 3, 13, 16]( Figure 1). Finally,
the oligomeric state of FPN1 has also been debated for
several years: the protein has been reported to be a monomer
[12, 15, 17]a sw e l la sad i m e r / m u l t i m e r[ 14, 18]. A recent
study by using recombinant expression of FPN1 in insect
cellsandabiophysicalcharacterizationofpuriﬁeddetergent-
solubilized FPN1 showed that FPN1 protein is a monomer,
having 12 transmembrane regions and N- and C-termini
bothcytosolic[19].Inthe5 -UTRofFPN1mRNAaputative
iron responsive element (IRE) was found that could confer a
translational regulation by iron regulatory proteins (IRPs) in
a manner similar to other 5 -UTR-IRE-regulated genes, that
is, ferritin, erythroid δ-aminolevulinate synthase (ALAS2)
and mitochondrial aconitase [1, 20]. The 5 -UTR-FPN1-IRE
was responsive to iron in HepG2 and CaCo2 cells [21]; in
vitro iron deprivation inhibited translational eﬃciency of
FPN1 mRNA [4, 6, 22]. However, the regulation of FPN1
expression by iron is currently poorly understood and a
direct proof of IRP-IRE control has not been provided yet.
Both transcriptional and post-transcriptional mechanisms
have been implicated in the regulation of FPN1 induced
by changes in cellular iron status [2, 23]. Some authors
demonstrated that hepcidin, a major regulator of iron
metabolism, binds to FPN1 in tissue culture cells, resulting2 Advances in Hematology
in internalization and degradation of FPN1 and in decreased
exportofcellulariron[24].Thepost-translationalregulation
of FPN1 by hepcidin may thus complete a homeostatic loop:
iron regulates secretion of hepcidin, which then reduces
export of cellular iron [24].
2. Ferroportin and IronOverload Disorders
Ferroportin disease, or type 4 hemochromatosis, or HFE4, is
an autosomal dominant condition with heterozygous muta-
tions in the FPN1 gene [23]. Hemochromatosis associated
with mutation in FPN1 can result in two diﬀerent types of
iron loading: one type is phenotypically indistinguishable
from classical HFE hemochromatosis, in that the patients
have both an elevated transferrin saturation and serum
ferritin, while the other type termed “ferroportin disease”
is associated with microcytic anemia, a raised serum ferritin
and iron deposition in macrophages rather than hepatocytes
[23]. FPN1 mutations may have three possible eﬀects:
causing misfolding of the protein and failure to reach
the cell surface (“loss of function”) [10] or producing a
mutant protein that is expressed at the cell surface but is
not inhibited by hepcidin (“loss of regulation”) [11], or
aﬀecting iron transport ability [18]. Brieﬂy it was shown
that A77D, V162del, G490D, and D157G mutations, that are
associated with typical pattern of disease in vivo, cause a
loss of iron export function in vitro, but do not physically
or functionally impede FPN1 protein coded by the wild-
type allele [10, 11, 18] and, therefore, lead to disease
by haploinsuﬃcieny. These results are consistent with the
schemeproposedbyMontosietal.[25]toexplaintheclinical
phenotype observed in patients with these mutations [10]:
lower level of serum iron, resulting from iron sequestration
in macrophages, reduces availability to the bone marrow
for erythropoiesis, thus leading to a middle anemia in the
early stages of disease that was eﬀectively observed in some
patients and that respond poorly to phlebotomy [10, 26].
So iron overload may be a consequence of the erythron
signalling to the gut enterocyte to increase iron uptake
from the diet to compensate for the anemia. According to
recent progress in this ﬁeld it is likely that the erythron
signalling is directly working through hepcidin-ferroportin
interaction. By contrast the Y64N, N144D, Q248H, and
C326Y mutations, which can be associated with greater
transferrin saturation and more prominent iron deposition
in liver parenchyma in vivo, retain iron export function
in vitro [10, 11]. It was postulated that this group of
mutations may resist inhibition by hepcidin, so interfering
with its homeostatic negative feedback loop and resulting in
a permanently “turned on” iron exporter [10, 11].
3. OverallView on Hematopoiesis and
Importance of Iron Homeostasis during
ErythroidCells Differentiation
Iron homeostasis depends on a coordinated regulation of
molecules involved in the import of this element and those
exporting it out of the cells. In some cell types, such as ery-
throid cells, iron import mechanisms are highly expressed,
thus allowing massive iron uptake [27, 28]. Excessive iron,
however, may be toxic for these cells, particularly in view of
its capacity to generate superoxide radicals and H2O2,w h i c h
m a yf r e e l yd i ﬀuse into the nucleus resulting in cell damage
[29]anditseemedthereforeofinteresttoinvestigatewhether
erythroid cells possess speciﬁc mechanisms for iron export.
Within the hematopoietic diﬀerentiation, the maintenance
of iron homeostasis is essential for erythroid cells and
macrophages. Erythroid cells need to incorporate very high
amounts of iron to support the continued synthesis of heme
and hemoglobin, while the macrophage cells play a key role
in iron storage and recycling [30–32]. Human erythropoiesis
is a dynamic complex multistep process that involves diﬀer-
entiationofpluripotenthematopoieticstemcells(HSCs)and
earlymultipotentprogenitors(MPPs)togeneratecommitted
erythroid precursors, the erythroblasts, which then give rise
to mature erythrocytes, that is, the red blood cells (RBCs)
[33–36]. Brieﬂy, the early erythroid progenitors (BFU-E,
burst-formingunits-erythroid)diﬀerentiateintolatecolony-
forming units erythroid (CFU-E) and proerythroblasts fol-
lowed by a progressive wave of erythroblast maturation in
polychromatic and orthochromatic erythroblasts coupled
with a gradual increase of erythroid-speciﬁc markers. As the
hematopoietic process progresses from the early stages into
erythroid cell maturation, cells gradually lose their potential
for cell proliferation and become mature enucleated cells.
Mature erythrocytes are biconcave disks without mitochon-
dria and other organelles but full of hemoglobin able to
bind and deliver O2 [33, 37–39]. The hematopoietic diﬀer-
entiation is a highly complex system in which, from a pool
of totipotent stem cells, originate all the cells of peripheral
blood [40–43]. Developmentally, hematopoiesis in humans
is characterized by three fundamental periods of activity
progressively involving the yolk sac, fetal liver and bone
marrow [44]. The survival, proliferation and diﬀerentiation
of hematopoietic stem and progenitor cells are regulated
by a complex network of hematopoietic growth factors
collectively known as colony stimulating factors (CSFs),
interleukins (ILs) or hemopoietins that are released from
accessorycellssuchasﬁbroblasts,macrophages,lymphocytes
and endothelial cells. Depending on their mechanism of
action during hematopoietic diﬀerentiation, these factors
can be classiﬁed into three categories: the ﬁrst category
includes growth factors that exert their action at the earliest
stages of hematopoiesis, for example, the c-kit receptor
ligand (KL) or stem cell factor (SCF) [45], FLT-3 ligand
(FL) [46, 47], the basic ﬁbroblast growth factor (bFGF)
[48,49],andinterleukin-6(IL-6)[50];inthesecondcategory
are growth factors acting as multilineage, whose prototypes
are the IL-3 and GM-CSF that are able to stimulate
primitive progenitors to proliferate and diﬀerentiate into all
hematopoietic lineage [51]; and ﬁnally in the third category
are included the growth factors acting as unilineage, that is,
those that stimulate the diﬀerentiation and proliferation of a
single lineage and include erythropoietin (EPO) [52, 53], the
granulocytic growth factor (G-CSF) [54], monocytic growth
factor (M-CSF) [55] and thrombopoietin (TPO) [56]. TheseAdvances in Hematology 3
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Figure 1: Membrane topology of FPN1. Topology of FPN1 protein is schematically represented, modiﬁed from two alternative models
proposed by Devalia et al. (on the top) [16] and Liu et al. (on the bottom) [13]: the 9 or 12 predicted transmembrane helices (vertical
green rectangles) are shown in relation to the lipid bilayer (horizontal violet rectangle). The positions of the mutations are marked as orange
circles. The N- and C-termini are denoted by N and C, respectively. The length of extra-membranous segments is indicated.
unilineage factors act on progenitors already moving toward
an hematopoietic lineage and promote the production of
mature cells in the circulating blood, that is, erythro-
cytes, neutrophils, eosinophils, monocytes/macrophages and
megakaryocytes. The circulating red cell mass is maintained
constant by a homeostatic mechanism regulating erythro-
poiesis, based on an erythropoietic stimulus which ensures
that, under physiological conditions, the production of red
blood cells equals their destruction. Moreover, in response
to hypoxia, hemorrhage or hemolysis, this stimulus causes
increase in the production of red blood cells [30]. Senescent
or damaged erythrocytes are phagocytized by macrophages
of reticuloendothelial system that play a key role in recycling
iron from hemoglobin [30].
4 .T h eP r e s e n c eo fF e rr o po rtinin
ErythroidCells
We reported for the ﬁrst time the expression of FPN1 mRNA
and protein in normal human erythroid cells at all stages
of diﬀerentiation [57]. This ﬁnding was very surprising,
becausethepresenceofatransporter,thatintheothertissues
is appointed to export iron, was not expected for red blood
cells, in which iron is believed to be all retained into the cell,
committed for heme synthesis, and to exit only after death
of these cells by macrophage phagocytosis. The IRE element
in the 5 -UTR of FPN1 mRNA was demonstrated to be
functionalinerythroidcellsandabletomediatetranslational
modulation by cellular iron levels [57]. Nonetheless, FPN1
protein expression appeared to maintain a constant level
during diﬀerent steps of erythroid diﬀerentiation and after
iron treatments [57]. This paradox would have been diﬃcult
to explain, unless of supposing the existence of a FPN1
transcript noncontaining the IRE element in erythroid cells.
Actually previous studies already indicated the possibility
of an IRE-independent regulation of FPN1 in diﬀerent
tissues and cell types, that is, iron deﬁciency was reported
to induce in mouse, human and rat duodenum, both in
vivo and in vitro, a signiﬁcant increase of FPN1 mRNA
expression [3, 7, 35, 58]. A nonIRE FPN1 transcript has
been previously only described in polycythaemia mice as
an aberrant mRNA resulting from a microdeletion in the
FPN1 gene promoter [6, 59]. So, we also described for the
ﬁrst time the existence of two alternative FPN1 transcripts
(variant II and III), other than the IRE-containing canonical
one (variant I), that did not contain the IRE element in
their 5 -UT region, did not respond to iron treatments
and together accounted for more than half of total FPN14 Advances in Hematology
mRNA present in erythroid cells [57]( Figure 2). These
transcripts arise from the usage of alternative upstream
promoters and diﬀerential splicing of 5 -UTR sequences.
Interestingly, these transcripts were expressed mainly dur-
ing the middle steps (4–11 days) of in vitro erythroid
diﬀerentiation, corresponding to the maturation from late
erythroid progenitors to polychromatophilic erythroblasts
(Figure 3). At these stages of erythroid diﬀerentiation TfR1,
the receptor responsible for iron incoming in erythroid
cells, is strongly and increasingly expressed [28]. Therefore,
the nonIRE (variant II and III) FPN1 transcripts were
expressed when erythroid progenitor/precursor cells need
to accumulate iron into the cells [57]. We speculated that
expression of the nonIRE FPN1 transcripts could produce
a constant level of the transporter, unresponsive to the
very high-iron levels present in maturing erythroid cell.
In contrast, IRE-containing FPN1 transcripts were mainly
expressed in undiﬀerentiated erythroid progenitors and in
mature terminal erythroblasts, suggesting a possible role at
these particular stages of erythroid diﬀerentiation [57]. The
existence of multiple FPN1 alternative transcripts indicated
a complex regulation of the FPN1 gene in erythroid cells
and the possibility that the control of FPN1 expression by
iron conditions in diﬀerent cell types might be complex. We
also speculated that in erythroid cells the regulation of FPN1
mRNA translation through the 5 -UTR IRE mechanism
might be silenced because in this cell type a high level
of iron uptake is needed to accumulate high amounts
of iron required for optimal heme synthesis. A solution
for this problem might be the utilization of an upstream
alternative promoter to produce mRNA species in which the
5 -UTR IRE might be spliced out or made nonfunctional
[57]( Figure 2). Our results showed that alternative FPN1
transcripts are diﬀerentially expressed during erythroid dif-
ferentiation, in particular indicating a sequential and speciﬁc
activation pathway, with an apparently mutual exclusion
between variant I IRE and variant II/III not containing
the IRE transcripts [57]. These observations suggest that
erythroid precursor cells need FPN1 transcript without a
IRE to evade translational control by IRP-IRE system in
order to export iron during the critical period when cells
are committed to proliferate and diﬀerentiate. Once the
precursor erythroid cells begin to produce hemoglobin,
FPN1 without a IRE diminishes and FPN1 with a IRE
predominates allowing erythroid cells to limit iron export
through the IRP-IRE system and synthesize heme without
developing microcytic anemia. Comparison between the
sequence of our variant II mRNA and aberrant nonIRE
FPN1 transcript previously reported in polycythaemia mice
[59] indicated a strong homology, thus strengthening our
hypothesis. Recently other authors have demonstrated that
also mouse duodenal epithelial cells utilized an alternative
upstream promoter to express a FPN1 transcript, named
FPN1B, which lacks the IRE, is not repressed in irondeﬁ-
cient conditions and enables duodenal enterocytes to evade
translational repression [60]. Enterocyte is a particular type
of cell because it must provide iron to satisfy systemic
iron demands regardless of whether enterocyte itself is iron
depleted [60]. The authors have so formulated a satisfactory
modelofwhyFPN1Bissigniﬁcantlyexpressedinduodenum.
According to this model in iron-replete conditions both
FPN1A and FPN1B transcripts are translated into FPN1
protein, which traﬃcs to the basolateral membrane to
transport iron into the circulation [60]. When the iron
stores are high, the liver produces hepcidin, which causes
ferroportin degradation and blocks iron absorption [24]. On
the contrary in iron-deﬁcient conditions, the liver ceases to
produce hepcidin and the degradation of FPN1 is eliminated
[60]. So the iron deﬁciency activates the IRE/IRP system
which in turn blocks FPN1A translation via the IRE element.
SoitappearsthatFPN1Btranscripthasakeyphysiologicrole
in duodenal cells: translation of FPN1B is not repressed by
IRPs allowing suﬃcient iron export to satisfy the systemic
iron demands [60]. They also demonstrated the presence of
FPN1B transcript in mouse bone marrow and in erythroid
precursor MEL and G1E cell lines [60] showing a regulation
comparable with our no-IRE FPN1 previously described
in human, thus supporting our hypothesis that ferroportin
may be subject to diﬀerent regulation depending on cell
type and its functions [57]. This mouse FPN1B transcript
was homologous to our nonIRE variant II FPN1 transcript
observed in human progenitor erythroid cells suggesting
that the utilization of an upstream alternative promoter to
produce mRNA species without IRE could be a physiologic
and tissue-speciﬁc regulation mechanism conserved during
mammalian evolution. The identiﬁcation of FPN1B reveals
how FPN1 expression can bypass IRP-dependent repression
in intestinal iron uptake, even when cells throughout the
body are iron deﬁcient [60]. Finally, in erythroid precursor
cells, they hypothesized that FPN1B expression enhances
real-time sensing of systemic iron status and facilitates
restriction of erythropoiesis in response to low-systemic iron
in order to not create microcythemia [60]. The existence of
FPN1 alternative transcripts unresponsive to regulation by
IRE-IRP system in the duodenum and erythroid precursor
cells suggests a cell type and tissue-speciﬁc control of
FPN1 expression by systemic iron status. Previous evidence
for diﬀerential eﬀects of hepcidin in machrophages and
intestinal epithelial cells can thus be explained [61].
5. Evidence for a Link betweenErythropoiesis
andFerroportin-Hepcidin Way Regulation
In recent years there has been important advancement in
our understanding of iron metabolism, mainly as a result
of the discovery of hepcidin [62–64], a key regulator of
whole body iron homeostasis (for an exhaustive review see
[65–67]). Increasing experimental evidence suggested that a
single molecule could be the “stores”, the “erythropoietic”
and the “inﬂammation” regulator of iron absorption and
recycling [68, 69], and that hepcidin acted principally or
solely by binding to ferroportin, the only known cellular
iron exporter, causing ferroportin to be phosphorylated,
internalized, ubiquitylated, sorted [24] through the multi-
vesicular body pathway and degraded in lysosomes [24, 70].
The aim of this review is beyond a complete picture of
current knowledge on the hepcidin regulation, therefore weAdvances in Hematology 5
1Kb
1 2 34 5 6 78
Ferroportin 1 gene
AAA
200bp
P3 P2 P1
IRE 1 2
Variant
I( I R E )
II A
II B
III A
III B
III C
Exon 1 (IIIA/B)
Exon 1 (IIIA/B)
Exons 1 (IIIC) 2 (IIIC)
Exon 1 (IIA)
Exon 1 (IIB)
Exon 1
Exon 1’
Exon 1’
Exon 1’
Exon 1”
Exon 1’
Exon 2
Predicted
protein
p571
p571
p571
p615
p596
p645
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will focus only on those aspects that we believe inﬂuence
erythropoiesis directly or indirectly. Diﬀerent stimuli can
modulate hepcidin and act as positive or negative regulators.
At the moment we know four major regulatory pathways
(erythroid, iron store, inﬂammatory and hypoxia-mediated
regulation) that act through diﬀerent signaling pathways to
control the production of hepcidin. It is obvious that this
complex network of interactions must be subjected to very
close control in order to ensure that the iron erythropoietic
demand is met and, in turn, adequate concentrations of
iron in the circulation are always present (for a complete
review see [66]). Under normal conditions iron store and
inﬂammatory regulation activate hepcidin transcription in
the hepatocytes through the bone morphogenetic proteins
(BMPs)/SMAD4 and signal transducer and activator of
transcription-3(STAT-3)pathways,respectively[66,71].The
hemochromatosisproteinHFE,transferrinreceptor2(TfR2)
and the membrane isoform of hemojuvelin (mHJV) are
all positive modulators of hepcidin transcription and when
defective, lead to hemochromatosis (HH) in humans [66,
72]. Oppositely, hypoxia, anemia, increased erythropoiesis
and reduced iron stores all negatively regulate hepcidin
expression [66]. Emerging evidence suggests that ery-
thropoiesis modulates hepcidin expression, with increased
erythropoietic activity suppressing the action of hepcidin
[73–77]. This in turn facilitates export of iron from the
reticuloendothelial system and enterocytes, increasing the
availability of iron for erythropoiesis [73, 76]. Anemia
and hypoxia also suppress hepcidin expression, although
recent experiments indicate that functional erythropoiesis
is required [73, 76, 77] for these conditions to regulate
hepcidin expression. We have thus reached the issue that
most concerns us: erythropoiesis and iron metabolism are
extremely intertwined in that alteration of one of the two
may have a major impact on the second (for complete
knowledge on the topic see [66, 78–83]). That is the reason
why thalassemia intermedia and thalassemia major are the
best studied human models of hepcidin modulation by inef-
fective erythropoiesis. Progressive iron overload is the most
salient and ultimately fatal complication of beta-thalassemia.
Iron deposition occurs in visceral organs (mainly in the
heart, liver and endocrine glands), causing tissue damage
and ultimately organ dysfunction and failure. Both transfu-
sional iron overload and excess gastrointestinal absorption
are contributory. Paradoxically, excess gastrointestinal iron
absorption persists despite massive increases in total body
iron load [68, 81, 83]. However, little is known about the
relationship among ineﬀective erythropoiesis, the role of
iron-regulatory genes, and tissue iron distribution in beta-
thalassemia. If iron were a dominant regulator, patients
with beta-thalassemia should express very high levels of
hepcidin in serum; in contrast, the levels are very low,
suggesting that the ineﬀective erythropoiesis alone is able to
suppress the synthesis of hepcidin in spite of the presence
of a severe iron overload [66, 81]. Furthermore, serum
from patients with thalassemia inhibited hepcidin mRNA
expression in the HepG2 cell line, which suggested the
presence of a humoral factor that downregulates hepcidin
[84]. The nature of the erythropoietic regulator of hepcidin
is still uncharacterized, but may include one or more
proteins during active erythropoiesis. Recent observations
in thalassemia patients has suggested that one of these
regulators could be the cytokine growth diﬀerentiation
factor-15 (GDF15) [66, 85]. GDF15 is a divergent member
of the transforming growth factor-beta superfamily that is
secretedbyerythroidprecursorsandothertissues.Ithasbeen6 Advances in Hematology
identiﬁed as an oxygen-regulated transcript responding to
hypoxia and as a molecule involved in hepcidin regulation
[85–91]. Serum from thalassemia patients suppressed hep-
cidin mRNA expression in primary human hepatocytes and
depletion of GDF15 reversed the hepcidin suppression [66,
85].ItwassuggestedthatGDF15overexpressionarisingfrom
an expanded erythroid compartment contributed to iron
overload in thalassemia syndromes by inhibiting hepcidin
expression, possibly by antagonizing the BMP pathway [66,
85]. Without going into a detailed analysis of the GDF15
regulation mechanisms, we would like to recall the results
obtained recently, that are in our view important to start
reﬂecting on the existence of alternative ways that regulate
hepcidin production. Very high levels of serum GDF15 were
also observed in patients with congenital dyserythropoietic
anemia type 1 (CDA I) suggesting that GDF15 contributes
to the inappropriate suppression of hepcidin with subse-
quent secondary hemochromatosis in these patients [66,
92]. Recently a very interesting study demonstrated that
expression of both GDF15 mRNA and protein was strongly
and speciﬁcally responsive to intracellular iron depletion in
a number of human cell lines and in vivo in humans [93].
This upregulation is independent of IRP1, IRP2 and the
HIF pathway suggesting the involvement of a novel iron-
regulatory pathway [93]. This study showed that GDF15
was induced by overexpression of wild-type ferroportin [93].
This observation is very intriguing because it connects the
iron-mediated regulation of GDF15 concentration to patho-
physiological levels of iron: despite systemic iron overload,
ineﬀective erythropoiesis and associated iron-ﬂuxes in beta-
thalassemia might generate an iron deﬁciency signal in a
relevant molecular or cellular context and consequent stim-
ulation of GDF15 expression in a particular erythroid com-
partment [93]. Recent literatures provided at least two more
molecules potentially involved in the regulation of hepcidin
by erythropoiesis, that is, the human twisted gastrulation
factor (TWSG1) [94] and the Oncostatin M (OsM) [95, 96].
IncontrasttoGDF15,thehighest-levelexpressionofTWSG1
was detected at early stages of erythroblast diﬀerentiation
before hemoglobinization of the cells [94]. In human cells,
TWSG1 suppressed hepcidin through a BMP-dependent
mechanism [94]. In vivo studies on thalassemic mice showed
that TWSG1 expression was signiﬁcantly increased in the
spleen, bone marrow and liver [94]. So it was proposed
that TWSG1 might act with GDF15 to dysregulate iron
homeostasis in beta-thalassemia [94]. In contrast to GDF15
and TWSG1, recent observations have showed that OsM
could induce hepcidin expression in human hepatoma cell
lines mainly through the JAK/STAT pathways [95]. Finally,
results obtained by HuH7 hepatoma cells cocultered with
primary human erythroblasts or erythroleukemic UT7 cells
presented a 20- to 35-fold increase of hepcidin expression
[96] and identiﬁed OsM responsible for increased levels
of hepcidin [96]. Furthermore, this study described the
biological involvement of OsM in iron metabolism “in vivo”
through direct transcriptional regulation of hepcidin gene
expression and suggested a new OsM-hepcidin axis that
might be critical in the development of hypoferremia in
inﬂammation [96].
6. Role andRegulation of Ferroportin in
ErythroidCells
The focus of this review is an update about the role of
FPN1 during human normal and pathological erythroid
diﬀerentiation. There is still much work to do but we think
that the likely existence of alternative transcripts altered
expression in all situations of ineﬀective erythropoiesis will
give answers to unresolved issues. In erythroid cells FPN1
could be part of the signaling pathway through which the
erythron communicates iron needs to expand the erythroid
compartment regardless of systemic iron level. Evidence of
a nonIRE FPN1 transcript in enterocytes of the duodenum
supports our belief in a setting far more complex and
speciﬁc to cell type. We also previously demonstrated the
existence of a FPN1 variant IIIA alternative transcript with
the potential to code for a longer protein with 44 additional
amino acids (p615), and a FPN1 variant IIIC alternative
transcript that potentially coded for a long protein with 74
additional amino acids (p645), both N-terminal to and in
framewiththecanonicalopenreadingframe[57](Figure 2).
Only FPN1 variant 1-IRE transcript has an IRE sequence in
the 5 UTR, whereas all the other transcript types do not.
Unfortunately all these transcripts diﬀer by 100-200 bp in
length and cannot be easily detected as distinct bands in
Northern analysis [57]. Interestingly, also these transcripts
were expressed mainly during the middle steps 4–11 days of
invitroerythroiddiﬀerentiation,correspondingtothematu-
rationfromlateerythroidprogenitorstopolychromatophilic
erythroblasts [57]( Figure 3). Therefore, the nonIRE (variant
II and III) FPN1 transcripts were expressed when erythroid
progenitor/precursor cells need to accumulate iron in the
cell [57]. At the moment we do not know yet whether the
hypothetical isoforms p615 and p645 are actually present in
vivo because of the diﬃculty of obtaining speciﬁc antibodies.
As mentioned earlier, to explain the surprising ﬁnding
that FPN1 protein expression was not responsive to iron
conditions although about 50% of FPN1 is encoded by the
IRE transcript, we speculated that in erythroid cells the
regulation of FPN1 mRNA expression through the 5 -UTR
IRE mechanism might be silenced because in this cell type
is needed to accumulate large amounts of iron for optimal
heme synthesis [57]a n das o l u t i o nt ot h i sp r o b l e mc o u l d
be to use an upstream alternative promoters to produce
mRNA species in which the 5 - U T RI R Ec o u l db es p l i c e d
out or made nonfunctional. Several studies support our
hypothesis: a recent work has shown an high frequency of
alternative ﬁrst exons in erythroid genes suggesting a critical
role in regulating gene function [97]. In the opinion of
the authors the frequent presence of consensus translation
initiation sites among the alternative ﬁrst exons suggests
that many proteins have alternative N-terminal structures
whose expression can be coupled to promoter choice [97].
So it seems that ﬁrst exons and alternative promoters are
more widespread in the human genome than previously
appreciated and that they may play a chief role in regulating
expression of selected protein isoforms in a tissue-speciﬁc
manner [97]. Recently it was also demonstrated that many
non productive transcriptional initiation events occurredAdvances in Hematology 7
in the vicinity of established promoters, some of which
may produce mRNAs with altered translation eﬃciency,
allowing transcripts to evolve to meet speciﬁc physiological
needs [98]. In conclusion we would like to emphasize that
the presence of alternative ferroportin transcripts without
an IRE in erythroid cells leaves open the possibility that
alterations in ferroportin mRNA splicing may be relevant in
pathological conditions of altered erythroid diﬀerentiation
[57, 59, 99]. So it would be interesting to investigate the
possibility of regulatory mutations in various iron disorders,
in particular when type 4 hemochromatosis is present in the
absence of coding region mutations or in all cases of familial
hyperferritinemia and in sporadic cases in the absence of
known secondary causes (i.e., inﬂammation, malignancy
infection or dysmetabolism) where “ferroportin disease”
should be suspected. We previously demonstrated that FPN1
protein appeared to be localized at the level of the cytoplasm
both in vesicles and in the cytosol in erythroid cells, suggest-
ing that FPN1 may be involved in the intracellular traﬃcking
of iron between the cytosol and organelles [57]. In contrast
tothecleardetectionofFPN1atthebasolateralmembraneof
enterocytes, immunoﬂuorescence studies with macrophages
revealed a pronounced vesicular and mostly intracellular
localization [100]. In particular confocal analysis revealed
the presence of some FPN1 microdomains at the plasma
membrane, likely suggesting a vesicular traﬃcking of the
protein between the cytosol and cell surface [100]. FPN1
might be stored within the cell until it is needed for iron
export, at which point it might be recruited to the mem-
brane [100]. Alternatively, FPN1 might mediate iron export
through the use of an intracellular vesicular compartment,
in which FPN1 would act as an iron “concentrator” [100].
Such a vesicular compartment could then be recruited to
the plasma membrane via exocytosis [100]. Furthermore,
although proteins required for heme biosynthesis and Fe-S
cluster assembly have been identiﬁed, we know little about
intracellular iron traﬃcking, particularly to mitochondria.
We do not exclude the possibility that FPN1 protein may
be involved in this pathway of iron metabolism. Some
authors have demonstrated that heme derived from human
or murine red blood cells or from an exogenous source of
heme led to marked transcriptional activation of the FPN1
and HO1 genes [101]. Furthermore, the iron released from
heme catabolism subsequently stimulated the expression
of ferroportin mRNA and protein, indicating the existence
of a dual mechanism of ferroportin regulation in this
cell model, characterized by an early induction of gene
transcription mediated primarily by heme, followed by a
post-transcriptional regulation iron mediated [101]. So it is
thereforetemptingtospeculatethatsimilarregulatorymech-
anisms could be involved in the transcriptional regulation of
FPN1byhemeinerythroidcells.Besidesitsfunctionaspros-
thetic group in heme proteins, heme itself can inﬂuence gene
expression at the level of transcription, protein synthesis,
microRNA processing or post-translational modiﬁcations.
Hemeisapotentinducerofhemeoxygenase1(HO1),acyto-
protective and anti-inﬂammatory molecule which catalyzes
heme degradation. Heme inactivates the transcriptional
repressor Bach1, thereby allowing the binding of Nrf2 to
Maf recognition elements (MAREs) present in the regulatory
regions HO1 [102, 103]. MAREs are also present in the
enhancer of the H ferritin gene [102, 104] or in the ß globin
Locus Control Region [102, 105]. Although HO1 expression
has not been extensively studied in erythroid cells, it has
been shown that HO1 mRNA decreases following erythroid
diﬀerentiationofFrienderythroleukemiacells,whilemRNAs
coding for the enzymes of the heme biosynthetic pathway
increase [102, 106]. Furthermore, it was previously reported
thathememediatedderepressionofMafrecognitionelement
through direct binding to transcription repressor Bach1
[107]; Nrf2 transcription factor regulated induction of the
heme oxygenase-1 gene [108] and coordinately regulated a
group of oxidative stress-inducible genes in macrophages
[109]; Bach1 was a sensor of cellular heme levels [110].
A very recent study has showed that heme controlled the
transcription of the iron exporter FPN1 involving Bach1
activity, Nrf2 nuclear accumulation and a highly conserved
MARE/ARE enhancer element located at position −7007/ −
7016 of the murine FPN1 promoter in macrophages [111].
This suggest that iron recycling from heme involves a
single transcription control mechanism that regulates heme
catabolism, iron storage and detoxiﬁcation as well as iron
export in a coordinated manner [111].
7. New PotentialTherapeutic Approaches
It is increasingly evident that the iron metabolism, heme
and cellular erythropoiesis are inextricably linked, because
iron metabolism [71, 112] and cellular heme (for exhaustive
review see [113]) are two of the most relevant key regulators
of erythropoiesis. The complex regulation of erythropoiesis
suggests the existence of several molecular targets that could
be exploited therapeutically for treatment of RBC disorders
like thalassemias and anemias [33]. We must diﬀerentiate
between primary iron overload, and iron overload that
accompanies ineﬀective erythropoiesis: in the latter case the
administration of hepcidin might be considered as a new
potential therapeutic approach to reduce iron overload in
thalassemias and other forms of anemia associated with
ineﬀective erythropoiesis [33]. The reduced number or
the absence of mature erythroid cells in beta-thalassemia
patientsisstillverydiﬃculttounderstand,andithasbecome
one of the paradoxes among the most diﬃcult to resolve
(as noted Stefano Rivella in one of his very comprehensive
review [83]): when the body has greater need for red blood
cells instead it responds by decreasing their production. The
mostprobablehypothesistoexplainthisphenomenonmight
rely on the existence of intrinsic and extrinsic mechanisms
that would aﬀect the process of diﬀerentiation: for example
in cells where the synthesis of beta-globin gene is defective
to the point that they ensure a stoichiometric between alpha
and beta globin chains, a security mechanism can block the
intrinsic maturation or, alternatively, an amount of heme in
excesscanbe an extrinsic signal toprevent the diﬀerentiation
that would lead to clusters of alpha globin chains production
of reactive oxygen species (ROS ) too toxic to survive [83].
There is much experimental evidence that oxidative stress
may limit the process of diﬀerentiation. All this of course8 Advances in Hematology
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Figure 3: Pathway of the erythropoiesis from progenitors to mature cells. Diﬀerent stages are indicated: hematopoietic stem cell (HSC),
burst-forminguniterythroid(BFU-E),colony-forminguniterythroid(CFU-E),proerythroblast(ProE),basophyilic(BasoE),polychromatic
(PolyE) and orthochromatic erythroblast (OrthoE). Coloured bars indicate timing of FPN1 alternative transcript expression (bottom) and
hemoglobin synthesis referred to stages of erythropoiesis (top).
worsens the anemic outline [83]. So the contribute of these
mechanisms to ineﬀective erythropoiesis might be diﬀerent
in each patient according to level of beta-globin synthesis
and other extrinsic factors such as iron overload [83]. At this
point the question arises: is there a meeting point between
diﬀerent signaling pathways, although activated by diﬀerent
signals? Recent discoveries indicate that there is a potential
for therapeutic intervention in beta-thalassemia by means
of manipulating iron metabolism [80, 83, 114]. A recent
study suggested a link between EpoR/Jak/Stat signaling and
iron metabolism, showing that in mice that completely lack
Stat5 activity the cell surface levels of TfR1 on erythroid
cells were decreased more than 2-fold [115]. Another study
suggested a direct involvement of Epo in hepcidin regulation
through the transcriptional factor C/EBP alpha [116]. In
addition it has been shown a link between Jak 2 and FPN1:
Jak2 phosphorylates FPN1 following binding of this protein
to hepcidin [117]. Phosphorylation of FPN1 then triggers
its internalization and degradation [117]. Therefore Jak2
might represent one of the major links at the interface
between erythropoiesis and iron metabolism suggesting
that use of Jak2 inhibitors, antioxidant, and analog of the
hepcidin might be used to reduce ineﬀective erythropoiesis
and abnormal iron absorption [83]. Administration of
synthetic hepcidin or of agents that increase its expression,
may be beneﬁcial in controlling absorption of this metal
[66]. Also GDF15 could be another potential therapeutic
target for beta-thalassemia syndromes [85]. A major goal
of hemoglobinopathy research is to develop treatments that
correct the underlying molecular defects responsible for
sickle cell disease and beta-thalassemia [114]. One approach
to achieving this goal is the pharmacologic induction of
fetal hemoglobin (HbF) [114]. Although many of the events
controlling the activity of the beta-globin locus are known,
the details of those regulating normal human hemoglobin
switching and reactivation of HbF in adult hematopoietic
cells remain to be elucidated. If the molecular events in
hemoglobin switching or gamma-globin gene reactivation
were better understood and HbF could be fully reactivated
in adult cells, the insights obtained might lead to a cure for
these disorders. Agents that increase human HbF in patients
may work at one or more levels: for example, hydroxyurea
and 5-azacytidine kill dividing cells preferentially and may
increase gamma-globin expression indirectly through this
eﬀect (for complete reviews see [114, 118]). Butyrate may
work both by HDAC inhibition and by increasing gamma-
globin translation on ribosomes [114, 118]. The Stem Cell
Factor (SCF) induced an “in vitro” expansion of eﬀective
erythropoiesis and a reactivation of gamma-globin synthesis
up to fetal levels, paving the way to its potential use in the
therapeutic treatment of this disease [119]. Recently it was
reportedtheabilityofthalidomidetoincreasegamma-globin
gene expression and the proportion of HbF-containing
c e l l si nah u m a ni nv i t r oe r y t h r o i dd i ﬀerentiation system
[120] showing that thalidomide induced production of
ROS that in turn caused p38 MAPK phosphorylation and
globally increased histone H4 acetylation [114, 120]. All
theseexperimentspresentabodyofevidencethatsuggestsan
important role for intracellular signaling in HbF induction
[114]. Finally recent publications have demonstrated the
importance of what has been termed the “integrated stress
response” pathway in erythroid cells that is also activated
from a variety of stress stimuli, including viral infection, NO,
heat shock, ROS, endoplasmic reticulum stress, ultraviolet
irradiation, proteosome inhibition, inadequate nutrients
and, in erythroid cells, limiting amounts of heme [114,
121, 122]. In conclusion we are increasingly convinced of
the importance to study the molecular mechanisms of ironAdvances in Hematology 9
homeostasis dysregulation in thalassemia and in particular
the GDF15-BMP-Hepcidin-Ferroportin regulatory way in
order to understand its contribution to iron overload.
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